Trends of cost and mortality of patients on haemodialysis with end stage renal disease

摘要: Aim The prevalence of end-stage renal disease in Taiwan is among the highest world. Treatment reimbursement for haemodialysis was capped 1996 order to contain costs. This study evaluated temporal changes costs and utilization medical care mortality patients receiving following reimbursement. Methods Using insurance claims data between 1998 2009, we established eight annual subcohorts with incident haemodialysis, increasing from 6099 7745 2005. With a 4-year follow-up paradigm each subcohort, resources use services, as well trends. Results The mean cost patient increased US $431 $737 emergency visits, $9007 $13 280 hospitalizations $79 141 $92 416 (16.8% increase) total costs, initial final subcohorts, respectively. Compared adjusted hazard ratio deaths declined 0.97 (95% CI 0.91 1.02) 1999 subcohort 0.86 0.82 0.91) 2005 (P trend <0.001). The corresponding cumulative probability decreased 45.5% 35.4%. Conclusions The annually, whereas overall despite haemodialysis. These results encourage further on reasons uses service hospitalization.